Search

Your search keyword '"Foley, A. Reghan"' showing total 442 results

Search Constraints

Start Over You searched for: Author "Foley, A. Reghan" Remove constraint Author: "Foley, A. Reghan"
442 results on '"Foley, A. Reghan"'

Search Results

1. CIAO1 loss of function causes a neuromuscular disorder with compromise of nucleocytoplasmic Fe-S enzymes

6. Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial

7. Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial

8. Variants in DTNA cause a mild, dominantly inherited muscular dystrophy

9. International retrospective natural history study of LMNA-related congenital muscular dystrophy

10. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial

11. Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy

12. Adult MTM1-related myopathy carriers: Classification based on deep phenotyping.

13. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy

14. Effects of HMGCR deficiency on skeletal muscle development

16. Childhood Onset Amyotrophic Lateral Sclerosis Associated with SPTLC2 Gain-of-Function Pathogenic Variants: Clinical, Genetic, and Biochemical Insights (P4-8.001)

17. Pathogenic TNNI1 variants disrupt sarcomere contractility resulting in hypo- and hypercontractile muscle disease

18. The recurrent deep intronic pseudoexon-inducing variant COL6A1 c.930+189C>T results in a consistently severe phenotype of COL6-related dystrophy: Towards clinical trial readiness for splice-modulating therapy

19. Intrathecal Gene Therapy for Giant Axonal Neuropathy

20. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

21. Clinical, immunohistochemical and genetic characterization of splice-altering biallelic DES variants: therapeutic implications

22. Loss of Function of the Cytoplasmic Fe-S Assembly Protein CIAO1 Causes a Neuromuscular Disorder with Compromise of Nucleocytoplasmic Fe-S Enzymes

23. Innocuous pressure sensation requires A-type afferents but not functional ΡΙΕΖΟ2 channels in humans

25. Cross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With SMCHD1 Variants

27. Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy.

28. Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis.

29. Recurrentde-novo gain-of-functionmutation inSPTLC2confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis

30. Recurrent de novoSPTLC2variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis

31. Association of Initial Maximal Motor Ability with Long-term Functional Outcome in Patients with COL6-related Dystrophies

32. A comprehensive study of skeletal muscle imaging in FHL1‐related reducing body myopathy

33. Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients

36. Recurrent de novo SPTLC2 variant causes childhoodonset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis.

37. Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies

38. Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy

39. Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium

40. Recurrent de-novo gain-of-functionmutation in SPTLC2confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis

41. An International Retrospective Early Natural History Study of LAMA2-Related Dystrophies

42. Recurrent de novo SPTLC2variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis

43. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy

44. Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies

48. A complex COL6A3 mutation identification: it takes an international village

49. BET1 variants establish impaired vesicular transport as a cause for muscular dystrophy with epilepsy

50. International retrospective natural history study of LMNA-related congenital muscular dystrophy Short Title: LMNA-CMD natural history

Catalog

Books, media, physical & digital resources